6 citations
,
November 2021 in “Frontiers in immunology” STAT3 signaling is important for healthy skin and hair follicles, and its disruption can lead to skin conditions like atopic dermatitis.
1 citations
,
January 2019 in “Annals of dermatology/Annals of Dermatology” STAT5 is crucial for hair growth in 3D cultured human dermal papilla cells.
June 2025 in “Animal Bioscience” miRNA-24 affects goat coat color by controlling proteins involved in pigment production.
1 citations
,
June 2025 in “Scientific Reports” Hydroxychloroquine may help treat benign prostatic hyperplasia by reducing inflammation and promoting cell death.
September 2024 in “Journal of the Pakistan Medical Association” A 589 nm laser increases IL-2 and IFN-y gene expression in human T-cells.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
95 citations
,
November 2018 in “Australasian journal of dermatology” Alopecia areata treatment varies, with no optimal method established yet.
November 2017 in “Asian journal of pharmaceutical and clinical research” Three compounds from Dadap leaves may help treat hair loss.
24 citations
,
June 2021 in “Journal of the European Academy of Dermatology and Venereology” Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.
January 2024 in “Wiadomości Lekarskie” Aortic aneurysm treatment has shifted to less invasive methods, improving safety and outcomes.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
April 2024 in “Frontiers in physiology” Immune cells are crucial for hair growth and preventing hair loss.
September 2023 in “Frontiers in medicine” The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
February 2026 in “Figshare” A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.
February 2026 in “Figshare” A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
99 citations
,
July 2017 in “Clinical Reviews in Allergy & Immunology” New treatments for Alopecia Areata show promise but need to be more effective and affordable.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.